Clonazepam
Tablet · Oral
Current shortage
Clonazepam, Tablet, .5 mg (NDC 0093-0832-05) – Available (Teva Pharmaceuticals USA, Inc., updated Sep 15, 2026)
Clonazepam, Tablet, 1 mg (NDC 72888-153-30) – Available (Rubicon Research Private Limited, updated Jun 1, 2026)
Marketed by Advagen Pharma Ltd.
Clonazepam, Tablet, 1 mg (NDC 16729-137-00) – Available (Accord Healthcare Inc., updated Sep 15, 2026)
Clonazepam, Tablet, .5 mg (NDC 72888-152-01) – Available (Rubicon Research Private Limited, updated Jun 1, 2026)
Marketed by Advagen Pharma Ltd.
Clonazepam, Tablet, 1 mg (NDC 43547-407-50) – Available (Prinston Pharmaceutical, Inc., updated Sep 2, 2026)
Marketed by Solco Healthcare
Clonazepam, Tablet, .5 mg (NDC 59651-722-01) – Available (Aurobindo Pharma USA, updated Jun 2, 2026)
Clonazepam, Tablet, 2 mg (NDC 16729-138-00) – Available (Accord Healthcare Inc., updated Sep 15, 2026)
Clonazepam, Tablet, 1 mg (NDC 0093-3212-05) – Available (Teva Pharmaceuticals USA, Inc., updated Sep 15, 2026)
Clonazepam, Tablet, 1 mg (NDC 43547-407-10) – Available (Prinston Pharmaceutical, Inc., updated Sep 2, 2026)
Marketed by Solco Healthcare
Clonazepam, Tablet, .5 mg (NDC 59651-722-99) – Available (Aurobindo Pharma USA, updated Jun 2, 2026)
Uses
Seizure Disorders: Clonazepam tablets are useful alone or as an adjunct in the treatment of the Lennox- Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). Panic Disorder: Clonazepam tablets are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam tablets was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lIlR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam tablets in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long- term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ).
Dosage and administration
Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole. Seizure Disorders: The use of multiple anticonvulsants may result in an increase of CNS depressant adverse effects. This should be considered before adding clonazepam tablets to an existing anticonvulsant regimen. Adults: The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg. Pediatric Patients: Clonazepam tablets are administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring. Geriatric Patients: There is no clinical trial experience with clonazepam tablets in seizure disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of clonazepam tablets and observed closely (see PRECAUTIONS, Geriatric Use ) . Panic Disorder: Adults: The initial dose for adults with panic disorder is 0.25 mg twice daily. An increase to the target dose for most patients of 1 mg/day may be made after 3 days. The recommended dose of 1 mg/day is based on the results from a fixed dose study in which the optimal effect was seen at 1 mg/day. Higher doses of 2, 3 and 4 mg/day in that study were less effective than the 1 mg/day dose and were associated with more adverse effects. Nevertheless, it is possible that some individual patients may benefit from doses of up to a maximum dose of 4 mg/day, and in those instances, the dose may be increased in increments of 0.125 to 0.25 mg bid every 3 days until panic disorder is controlled or until side effects make further increases undesired. To reduce the inconvenience of somnolence, administration of one dose at bedtime may be desirable. Treatment should be discontinued gradually, with a decrease of 0.125 mg twice daily every 3 days, until the drug is completely withdrawn. There is no body of evidence available to answer the question of how long the patient treated with clonazepam should remain on it. Therefore, the physician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Pediatric Patients: There is no clinical trial experience with clonazepam tablets in panic disorder patients under 18 years of age. Geriatric Patients: There is no clinical trial experience with clonazepam tablets in panic disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of clonazepam and observed closely (see PRECAUTIONS, Geriatric Use ) . Discontinuation or Dosage Reduction of clonazepam tablets: To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clonazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence ) .
Contraindications
Clonazepam tablets are contraindicated in patients with the following conditions: History of sensitivity to benzodiazepines Clinical or biochemical evidence of significant liver disease Acute narrow angle glaucoma (it may be used in patients with open angle glaucoma who are receiving appropriate therapy).
Warnings
Risks from Concomitant Use With Opioids: Concomitant use of benzodiazepines, including clonazepam tablets, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe clonazepam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when clonazepam tablets are used with opioids (see PRECAUTIONS; Information for Patients and PRECAUTIONS: Drug Interactions ). Abuse, Misuse, and Addiction: The use of benzodiazepines, including clonazepam tablets, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE: Abuse ) . Before prescribing clonazepam tablets and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of clonazepam tablets, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clonazepam tablets along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions: To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam tablets or reduce the dosage (a patient-specific plan should be used to taper the dose) (see DOSAGE AND ADMINISTRATION: Discontinuation or Dosage Reduction of Clonazepam Tablets ) . Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had long durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines, including clonazepam tablets, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of clonazepam tablets after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) (see DRUG ABUSE AND DEPENDENCE: Dependence ). Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months (see DRUG ABUSE AND DEPENDENCE: Dependence ) . Interference With Cognitive and Motor Performance: Since clonazepam tablets produces CNS depression, patients receiving this drug should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating machinery or driving a motor vehicle. They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during clonazepam tablets therapy (see PRECAUTIONS, Drug Interactions and PRECAUTIONS, Information for Patients ). Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs),including clonazepam tablets, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.
Precautions
General: Worsening of Seizures: When used in patients in whom several different types of seizure disorders coexist, clonazepam tablets may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal). This may require the addition of appropriate anticonvulsants or an increase in their dosages. The concomitant use of valproic acid and clonazepam tablets may produce absence status. Loss of Effect: In some studies, up to 30% of patients who initially responded have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Laboratory Testing During Long-Term Therapy: Periodic blood counts and liver function tests are advisable during long-term therapy with clonazepam tablets. Psychiatric and Paradoxical Reactions: Paradoxical reactions, such as agitation, irritability, aggression, anxiety, anger, nightmares, hallucinations, and psychoses are known to occur when using benzodiazepines (see ADVERSE REACTIONS: Psychiatric ). Should this occur, the use of the drug should be discontinued gradually (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence ). Paradoxical reactions are more likely to occur in children and in the elderly. Caution in Renally Impaired Patients: Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function. Hypersalivation: Clonazepam tablets may produce an increase in salivation. This should be considered before giving the drug to patients who have difficulty handling secretions. Respiratory Depression : Clonazepam tablets may cause respiratory depression and should be used with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, sleep apnea). Porphyria: Clonazepam tablets may have a porphyrogenic effect and should be used with care in patients with porphyria. Information for Patients: A clonazepam tablets Medication Guide must be given to the patient each time clonazepam tablets are dispensed, as required by law. Patients should be instructed to take clonazepam tablets only as prescribed. Physicians are advised to discuss the following issues with patients for whom they prescribe clonazepam tablets. Risks from Concomitant Use With Opioids Inform patients and caregivers that potentially fatal additive effects may occur if clonazepam is used with opioids and not to use such drugs concomitantly unless supervised by a health care provider (see WARNINGS: Risks from Concomitant Use With Opioids and PRECAUTIONS: Drug Interactions ) . Abuse, Misuse, and Addiction: Inform patients that the use of clonazepam tablets, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug (see WARNINGS: Abuse, Misuse, and Addiction and DRUG ABUSE AND DEPENDENCE ) Withdrawal Reactions: Inform patients that the continued use of clonazepam tablets may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of clonazepam tablets may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of clonazepam tablets may require a slow taper (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE ). Interference With Cognitive and Motor Performance : Because benzodiazepines have the potential to impair judgment, thinking or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that clonazepam tablets therapy does not affect them adversely. Suicidal Thinking and Behavior: Patients, their caregivers, and families should be counseled that AEDs, including clonazepam tablet, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. Pregnancy: Advise pregnant females that use of clonazepam tablets late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy ) . Instruct patients to inform their healthcare provider if they are pregnant. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant while taking clonazepam tablets. This registry is collecting information about the safety of antiepileptic drugs during pregnancy (see PRECAUTIONS: Pregnancy ) . Nursing : Instruct patients to inform their healthcare provider if they are breastfeeding or intend to breastfeed.
Side effects
The adverse experiences for clonazepam tablets are provided separately for patients with seizure disorders and with panic disorder. Seizure Disorders: The most frequently occurring side effects of clonazepam tablets are referable to CNS depression. Experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. In some cases, these may diminish with time; behavior problems have been noted in approximately 25% of patients. Others, listed by system, including those identified during postapproval use of clonazepam tablets are: Cardiovascular: Palpitations Dermatologic: Hair loss, hirsutism, skin rash, ankle and facial edema Gastrointestinal: Anorexia, coated tongue, constipation, diarrhea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gums Genitourinary: Dysuria, enuresis, nocturia, urinary retention Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase Musculoskeletal: Muscle weakness, pains Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy, weight loss or gain Neurologic: Abnormal eye movements, aphonia, choreiform movements, coma, diplopia, dysarthria, dysdiadochokinesis, “glassy-eyed” appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo Psychiatric: Confusion, depression, amnesia, hysteria, increased libido, insomnia, psychosis (the behavior effects are more likely to occur in patients with a history of psychiatric disturbances). The following paradoxical reactions have been observed: irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and abnormal dreams, hallucinations. Respiratory : Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages Panic Disorder: Adverse events during exposure to clonazepam tablets were obtained by spontaneous report and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, as noted below. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment- emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Adverse Findings Observed in Short-Term, Placebo-Controlled Trials: Adverse Events Associated With Discontinuation of Treatment: Overall, the incidence of discontinuation due to adverse events was 17% in clonazepam tablets compared to 9% for placebo in the combined data of two 6- to 9-week trials. The most common events (≥1%) associated with discontinuation and a dropout rate twice or greater for clonazepam tablets than that of placebo included the following: Table 2 Most Common Adverse Events (≥1%) Associated with Discontinuation of Treatment Adverse Event Clonazepam Tablets (N=574) Placebo (N=294) Somnolence 7% 1% Depression 4% 1% Dizziness 1% <1% Nervousness 1% 0% Ataxia 1% 0% Intellectual Ability Reduced 1% 0% Adverse Events Occurring at an Incidence of 1% or More Among Clonazepam Tablets-Treated Patients : Table 3 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during acute therapy of panic disorder from a pool of two 6- to 9-week trials. Events reported in 1% or more of patients treated with clonazepam tablets (doses ranging from 0.5 to 4 mg/day) and for which the incidence was greater than that in placebo-treated patients are included. The prescriber should be aware that the figures in Table 3 cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence in the population studied.
Drug interactions
Drug Interactions: Effect of Concomitant Use of Benzodiazepine and Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation. Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of carbamazepine or phenobarbital. Clonazepam has the potential to influence concentrations of phenytoin. Monitoring of phenytoin concentration is recommended when clonazepam is co-administrated with phenytoin. The effect of clonazepam on the metabolism of other drugs has not been investigated. Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics. In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the tablet was given with propantheline compared to when it was given alone. The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. Cytochrome P450 inducers, such as phenytoin, carbamazepine, lamotrigine, and phenobarbital induce clonazepam metabolism, causing an approximately 38% decrease in plasma clonazepam levels. Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents (e.g., fluconazole), should be used cautiously in patients receiving clonazepam because they may impair the metabolism of clonazepam leading to exaggerated concentrations and effects. Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis Carcinogenicity studies have not been conducted with clonazepam. Mutagenesis The data currently available are not sufficient to determine the genotoxic potential of clonazepam. Impairment of Fertility In a two-generation fertility study in which clonazepam was given orally to rats at 10 and 100 mg/kg/day, there was a decrease in the number of pregnancies and in the number of offspring surviving until weaning. The lowest dose tested is approximately 5 and 24 times the maximum recommended human dose (MRHD) of 20 mg/day for seizure disorders and 4 mg/day for panic disorder, respectively, on a body surface area (mg/m 2 ) basis. Pregnancy: Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as Clonazepam Tablets, during pregnancy. Healthcare providers are encouraged to recommend that pregnant women taking Clonazepam Tablets enroll in the NAAED Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome , and Clinical Considerations ). Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data). Administration of clonazepam to pregnant rabbits during the period of organogenesis resulted in developmental toxicity, including increased incidences of fetal malformations, at doses similar to or below therapeutic doses in patients (see Animal Data). Data for other benzodiazepines suggest the possibility of long-term effects on neurobehavioral and immunological function in animals following prenatal exposure to benzodiazepines at clinically relevant doses. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia and sedation in neonates. Monitor neonates exposed to Clonazepam Tablets during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to Clonazepam Tablets during pregnancy for signs of withdrawal. Manage these neonates accordingly (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome ). Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.
Pregnancy
Pregnancy: Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as Clonazepam Tablets, during pregnancy. Healthcare providers are encouraged to recommend that pregnant women taking Clonazepam Tablets enroll in the NAAED Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/. Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome , and Clinical Considerations ). Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see Data). Administration of clonazepam to pregnant rabbits during the period of organogenesis resulted in developmental toxicity, including increased incidences of fetal malformations, at doses similar to or below therapeutic doses in patients (see Animal Data). Data for other benzodiazepines suggest the possibility of long-term effects on neurobehavioral and immunological function in animals following prenatal exposure to benzodiazepines at clinically relevant doses. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia and sedation in neonates. Monitor neonates exposed to Clonazepam Tablets during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to Clonazepam Tablets during pregnancy for signs of withdrawal. Manage these neonates accordingly (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome ). Data Human Data Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. Animal Data In three studies in which clonazepam was administered orally to pregnant rabbits at doses of 0.2, 1, 5, or 10 mg/kg/day during the period of organogenesis, a similar pattern of malformations (cleft palate, open eyelid, fused sternebrae and limb defects) was observed at all doses, in a low, non-dose-related incidence. The lowest dose tested is less than the maximum recommended human dose (MRHD) of 20 mg/day for seizure disorders and similar to the MRHD of 4 mg/day for panic disorder, on a mg/m 2 basis. Reductions in maternal weight gain occurred at doses of 5 mg/kg/day or greater and reduction in embryofetal growth occurred in one study at a dose of 10 mg/kg/day. No adverse maternal or embryofetal effects were observed in mice or rats following oral administration of clonazepam during organogenesis of doses up to 15 or 40 mg/kg/day, respectively (4 and 20 times the MRHD of 20 mg/day for seizure disorders and 20 and 100 times the MRHD of 4 mg/day for panic disorder, respectively, on a mg/m 2 basis). Data for other benzodiazepines suggest the possibility of adverse developmental effects (long-term effects on neurobehavioral and immunological function) in animals following prenatal exposure to benzodiazepines. Nursing Mothers: Risk Summary Clonazepam is excreted in human milk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. There are no data on the effects of clonazepam on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clonazepam tablets and any potential adverse effects on the breastfed infant from the underlying maternal condition. Clinical Considerations Infants exposed to Clonazepam Tablets through breast milk should be monitored for sedation, poor feeding and poor weight gain. Pediatric Use: Because of the possibility that adverse effects on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use of clonazepam tablet is important in pediatric patients being treated for seizure disorder (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION ) . Safety and effectiveness in pediatric patients with panic disorder below the age of 18 have not been established. Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam tablets elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function.
Pediatric use
Pediatric Use: Because of the possibility that adverse effects on physical or mental development could become apparent only after many years, a benefit-risk consideration of the long-term use of clonazepam tablet is important in pediatric patients being treated for seizure disorder (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION ) . Safety and effectiveness in pediatric patients with panic disorder below the age of 18 have not been established. Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam tablets elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function. Because elderly patients are more likely to have decreased hepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic and/or renal function at the time of dose selection. Sedating drugs may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam tablets and observed closely.
Geriatric use
Geriatric Use: Clinical studies of clonazepam tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because clonazepam undergoes hepatic metabolism, it is possible that liver disease will impair clonazepam tablets elimination. Metabolites of clonazepam tablets are excreted by the kidneys; to avoid their excess accumulation, caution should be exercised in the administration of the drug to patients with impaired renal function. Because elderly patients are more likely to have decreased hepatic and/or renal function, care should be taken in dose selection, and it may be useful to assess hepatic and/or renal function at the time of dose selection. Sedating drugs may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of clonazepam tablets and observed closely.
Overdosage
Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal (see WARNINGS: Abuse, Misuse, and Addiction ). Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage. In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway maintenance. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. See the flumazenil injection Prescribing Information. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
Description
Clonazepam Tablets, USP, a benzodiazepine, is available as scored tablet with debossing Λ containing 0.5 mg of clonazepam and unscored tablets with debossing Λ, Λ and Λ containing 0.25 mg, 1 mg or 2 mg of clonazepam respectively. 66 L3 67 69 Each tablet also contains lactose monohydrate, polyethylene glycol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate with the following colourants: 0.25 mg-D & C Yellow 10 Al Lake, 0.5 mg-FD & C Yellow 6 Al Lake, D & C Yellow 10 Al Lake; 1 mg-FD & C Blue 1 Al lake and FD & C Blue 2 Al lake Chemically, clonazepam is 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- 2H -1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has a molecular weight of 315.72 and the following structural formula: image description
How supplied
Clonazepam Tablets USP, 0.25 mg are mottled yellow, round-flat faced beveled edge tablet, debossed with Λ on one side and plain on the other side. They are supplied as follows: L3 NDC 72888-497-01, bottles of 30 NDC 72888-497-02, bottles of 100 NDC 72888-497-03, bottles of 500 NDC 72888-497-04, bottles of 1000 Clonazepam Tablets USP, 0.5 mg are mottled orange, round, flat-faced, beveled edge tablet, debossed with Λ on one side and scored on the other side. They are supplied as follows: 66 NDC 72888-152-30, bottles of 30. NDC 72888-152-01, bottles of 100. NDC 72888-152-05, bottles of 500. NDC 72888-152-00, bottles of 1000. Clonazepam Tablets USP, 1 mg are mottled blue, round, flat-faced, beveled edge tablet, debossed with Λ on one side and plain on the other side. They are supplied as follows: 67 NDC 72888-153-30, bottles of 30. NDC 72888-153-01, bottles of 100. NDC 72888-153-05, bottles of 500. NDC 72888-153-00, bottles of 1000. Clonazepam Tablets USP, 2 mg are white to off-white, round, flat-faced, beveled edge tablets, debossed with Λ on one side and plain on the other side. They are supplied as follows: 69 NDC 72888-154-30, bottles of 30. NDC 72888-154-01, bottles of 100. NDC 72888-154-05, bottles of 500. NDC 72888-154-00, bottles of 1000. Store at 20°C to 25°C (68°F -77°F) [See USP Controlled Room Temperature]. All trademarks are the property of their respective owners. Dispense with Medication Guide and package Insert available at https://www.advagenpharma.com/medguide_pil/clonazepamtablets Manufactured by: Rubicon Research Ltd., Thane 421506, India. Distributed by: Advagen Pharma Ltd., East Windsor, NJ 08520, USA Revision: 05, 06/2026 image description
Patient information
Information for Patients: A clonazepam tablets Medication Guide must be given to the patient each time clonazepam tablets are dispensed, as required by law. Patients should be instructed to take clonazepam tablets only as prescribed. Physicians are advised to discuss the following issues with patients for whom they prescribe clonazepam tablets. Risks from Concomitant Use With Opioids Inform patients and caregivers that potentially fatal additive effects may occur if clonazepam is used with opioids and not to use such drugs concomitantly unless supervised by a health care provider (see WARNINGS: Risks from Concomitant Use With Opioids and PRECAUTIONS: Drug Interactions ) . Abuse, Misuse, and Addiction: Inform patients that the use of clonazepam tablets, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug (see WARNINGS: Abuse, Misuse, and Addiction and DRUG ABUSE AND DEPENDENCE ) Withdrawal Reactions: Inform patients that the continued use of clonazepam tablets may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of clonazepam tablets may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of clonazepam tablets may require a slow taper (see WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE ). Interference With Cognitive and Motor Performance : Because benzodiazepines have the potential to impair judgment, thinking or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that clonazepam tablets therapy does not affect them adversely. Suicidal Thinking and Behavior: Patients, their caregivers, and families should be counseled that AEDs, including clonazepam tablet, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers. Pregnancy: Advise pregnant females that use of clonazepam tablets late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns (see WARNINGS: Neonatal Sedation and Withdrawal Syndrome and PRECAUTIONS: Pregnancy ) . Instruct patients to inform their healthcare provider if they are pregnant. Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant while taking clonazepam tablets. This registry is collecting information about the safety of antiepileptic drugs during pregnancy (see PRECAUTIONS: Pregnancy ) . Nursing : Instruct patients to inform their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients who take clonazepam tablets to monitor their infants for excessive sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs (see PRECAUTIONS: Nursing Mothers ) Concomitant Medication: Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions. Alcohol: Patients should be advised to avoid alcohol while taking clonazepam tablets. Drug Interactions: Effect of Concomitant Use of Benzodiazepine and Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation. Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of carbamazepine or phenobarbital. Clonazepam has the potential to influence concentrations of phenytoin. Monitoring of phenytoin concentration is recommended when clonazepam is co-administrated with phenytoin. The effect of clonazepam on the metabolism of other drugs has not been investigated. Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics. In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the tablet was given with propantheline compared to when it was given alone.
Label text from the FDA structured product label by Advagen Pharma Ltd (revised Jun 25, 2026). Long sections are shortened; the complete label is on DailyMed.
Active ingredients
- Clonazepam in 140 products
Clonazepam NDC products (140)
| NDC | Strength & form | Labeler | Type |
|---|---|---|---|
| 50090-2022 | Clonazepam 1 mg/1 Tablet | A-S Medication Solutions | ANDA · DEA CIV |
| 50090-2088 | Clonazepam .5 mg/1 Tablet | A-S Medication Solutions | ANDA · DEA CIV |
| 50090-4841 | Clonazepam .5 mg/1 Tablet | A-S Medication Solutions | ANDA · DEA CIV |
| 16729-138 | Clonazepam 2 mg/1 Tablet | Accord Healthcare Inc. | ANDA · DEA CIV |
| 16729-137 | Clonazepam 1 mg/1 Tablet | Accord Healthcare Inc. | ANDA · DEA CIV |
| 16729-136 | Clonazepam .5 mg/1 Tablet | Accord Healthcare Inc. | ANDA · DEA CIV |
| 72888-136 | Clonazepam 1 mg/1 Tablet, Orally Disintegrating | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-154 | Clonazepam 2 mg/1 Tablet | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-133 | Clonazepam .125 mg/1 Tablet, Orally Disintegrating | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-134 | Clonazepam .25 mg/1 Tablet, Orally Disintegrating | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-135 | Clonazepam .5 mg/1 Tablet, Orally Disintegrating | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-137 | Clonazepam 2 mg/1 Tablet, Orally Disintegrating | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-152 | Clonazepam .5 mg/1 Tablet | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-497 | Clonazepam .25 mg/1 Tablet | Advagen Pharma Ltd | ANDA · DEA CIV |
| 72888-153 | Clonazepam 1 mg/1 Tablet | Advagen Pharma Ltd | ANDA · DEA CIV |
| 80425-0358 | Clonazepam .5 mg/1 Tablet | Advanced Rx of Tennessee, LLC | ANDA · DEA CIV |
| 80425-0125 | Clonazepam .5 mg/1 Tablet | Advanced Rx Pharmacy of Tennessee, LLC | ANDA · DEA CIV |
| 80425-0135 | Clonazepam 1 mg/1 Tablet | Advanced Rx Pharmacy of Tennessee, LLC | ANDA · DEA CIV |
| 80425-0357 | Clonazepam 1 mg/1 Tablet | Advanced Rx Pharmacy of Tennessee, LLC | ANDA · DEA CIV |
| 80425-0402 | Clonazepam .5 mg/1 Tablet | Advanced Rx Pharmacy of Tennessee, LLC | ANDA · DEA CIV |
| 62332-364 | Clonazepam .125 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Inc. | ANDA · DEA CIV |
| 62332-368 | Clonazepam 2 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Inc. | ANDA · DEA CIV |
| 62332-365 | Clonazepam .25 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Inc. | ANDA · DEA CIV |
| 62332-366 | Clonazepam .5 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Inc. | ANDA · DEA CIV |
| 62332-367 | Clonazepam 1 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Inc. | ANDA · DEA CIV |
| 46708-368 | Clonazepam 2 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Limited | ANDA · DEA CIV |
| 46708-367 | Clonazepam 1 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Limited | ANDA · DEA CIV |
| 46708-366 | Clonazepam .5 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Limited | ANDA · DEA CIV |
| 46708-365 | Clonazepam .25 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Limited | ANDA · DEA CIV |
| 46708-364 | Clonazepam .125 mg/1 Tablet, Orally Disintegrating | Alembic Pharmaceuticals Limited | ANDA · DEA CIV |
| 60687-872 | Clonazepam 1 mg/1 Tablet | American Health Packaging | ANDA · DEA CIV |
| 60687-861 | Clonazepam .5 mg/1 Tablet | American Health Packaging | ANDA · DEA CIV |
| 71610-771 | Clonazepam 1 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 67544-529 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-039 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-040 | Clonazepam 1 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-368 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-749 | Clonazepam 2 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-852 | Clonazepam 1 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-863 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-855 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-790 | Clonazepam .5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 71610-817 | Clonazepam 2 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA · DEA CIV |
| 59651-722 | Clonazepam .5 mg/1 Tablet | Aurobindo Pharma Limited | ANDA · DEA CIV |
| 59651-723 | Clonazepam 1 mg/1 Tablet | Aurobindo Pharma Limited | ANDA · DEA CIV |
| 59651-724 | Clonazepam 2 mg/1 Tablet | Aurobindo Pharma Limited | ANDA · DEA CIV |
| 50268-173 | Clonazepam .5 mg/1 Tablet | AvPAK | ANDA · DEA CIV |
| 50268-175 | Clonazepam 2 mg/1 Tablet | AvPAK | ANDA · DEA CIV |
| 50268-174 | Clonazepam 1 mg/1 Tablet | AvPAK | ANDA · DEA CIV |
| 72162-1364 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1206 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-8988 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 72162-1366 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-0022 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-0113 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-0333 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-1810 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-1843 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-2653 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1207 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-9747 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-1856 | Clonazepam 2 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-2414 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 71335-2509 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1205 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1203 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1116 | Clonazepam 1 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1201 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 63629-1202 | Clonazepam .5 mg/1 Tablet | Bryant Ranch Prepack | ANDA · DEA CIV |
| 55154-4318 | Clonazepam .5 mg/1 Tablet | Cardinal Health 107, LLC | ANDA · DEA CIV |
| 55154-4319 | Clonazepam 1 mg/1 Tablet | Cardinal Health 107, LLC | ANDA · DEA CIV |
| 62135-771 | Clonazepam 2 mg/1 Tablet | Chartwell RX, LLC | ANDA · DEA CIV |
| 62135-770 | Clonazepam 1 mg/1 Tablet | Chartwell RX, LLC | ANDA · DEA CIV |
| 62135-769 | Clonazepam .5 mg/1 Tablet | Chartwell RX, LLC | ANDA · DEA CIV |
| 58118-0154 | Clonazepam 2 mg/1 Tablet | Clinical Solutions Wholesale, LLC | ANDA · DEA CIV |
| 58118-0832 | Clonazepam .5 mg/1 Tablet | Clinical Solutions Wholesale, LLC | ANDA · DEA CIV |
| 58118-0153 | Clonazepam 1 mg/1 Tablet | Clinical Solutions Wholesale, LLC | ANDA · DEA CIV |
| 58118-0152 | Clonazepam .5 mg/1 Tablet | Clinical Solutions Wholesale, LLC | ANDA · DEA CIV |
| 67046-0493 | Clonazepam 1 mg/1 Tablet | Coupler LLC | ANDA · DEA CIV |
| 67046-0794 | Clonazepam 1 mg/1 Tablet | Coupler LLC | ANDA · DEA CIV |
| 67046-1521 | Clonazepam .5 mg/1 Tablet | Coupler LLC | ANDA · DEA CIV |
| 67046-1488 | Clonazepam 2 mg/1 Tablet | Coupler LLC | ANDA · DEA CIV |
| 72189-081 | Clonazepam .5 mg/1 Tablet | DIRECT RX | ANDA · DEA CIV |
| 72189-475 | Clonazepam 1 mg/1 Tablet | Direct_Rx | ANDA · DEA CIV |
| 0904-7227 | Clonazepam .5 mg/1 Tablet | Major Pharmaceuticals | ANDA · DEA CIV |
| 0904-7728 | Clonazepam 1 mg/1 Tablet | Major Pharmaceuticals | ANDA · DEA CIV |
| 72603-309 | Clonazepam 2 mg/1 Tablet | Northstar Rx LLC | ANDA · DEA CIV |
| 72603-308 | Clonazepam 1 mg/1 Tablet | Northstar Rx LLC | ANDA · DEA CIV |
| 72603-307 | Clonazepam .5 mg/1 Tablet | Northstar Rx LLC | ANDA · DEA CIV |
| 68071-5247 | Clonazepam 1 mg/1 Tablet | NuCare Pharmaceuticals,Inc. | ANDA · DEA CIV |
| 68071-3613 | Clonazepam 2 mg/1 Tablet | NuCare Pharmaceuticals,Inc. | ANDA · DEA CIV |
| 68071-4021 | Clonazepam .5 mg/1 Tablet | NuCare Pharmaceuticals,Inc. | ANDA · DEA CIV |
| 49884-309 | Clonazepam 1 mg/1 Tablet, Orally Disintegrating | Par Health USA, LLC | ANDA · DEA CIV |
| 49884-306 | Clonazepam .125 mg/1 Tablet, Orally Disintegrating | Par Health USA, LLC | ANDA · DEA CIV |
| 49884-307 | Clonazepam .25 mg/1 Tablet, Orally Disintegrating | Par Health USA, LLC | ANDA · DEA CIV |
| 49884-308 | Clonazepam .5 mg/1 Tablet, Orally Disintegrating | Par Health USA, LLC | ANDA · DEA CIV |
| 49884-310 | Clonazepam 2 mg/1 Tablet, Orally Disintegrating | Par Health USA, LLC | ANDA · DEA CIV |
| 72789-307 | Clonazepam .5 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 72789-314 | Clonazepam 1 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 72789-315 | Clonazepam 2 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 43063-797 | Clonazepam .5 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 43063-794 | Clonazepam 1 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 43063-788 | Clonazepam 2 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA · DEA CIV |
| 68788-8499 | Clonazepam 2 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA · DEA CIV |
| 68788-8473 | Clonazepam 1 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA · DEA CIV |
| 68788-8420 | Clonazepam .5 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA · DEA CIV |
| 68788-8401 | Clonazepam 1 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA · DEA CIV |
| 63187-226 | Clonazepam .5 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 82804-272 | Clonazepam 1 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 63187-603 | Clonazepam .5 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 63187-888 | Clonazepam 1 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 71205-827 | Clonazepam .5 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 71205-529 | Clonazepam 1 mg/1 Tablet | Proficient Rx LP | ANDA · DEA CIV |
| 70518-3849 | Clonazepam 2 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-1297 | Clonazepam .5 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-1521 | Clonazepam 1 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-1801 | Clonazepam .5 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-2232 | Clonazepam 2 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-2334 | Clonazepam 1 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-2507 | Clonazepam .5 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-2533 | Clonazepam 1 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-3144 | Clonazepam 1 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-3891 | Clonazepam .5 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-3960 | Clonazepam .5 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 70518-4074 | Clonazepam 1 mg/1 Tablet | REMEDYREPACK INC. | ANDA · DEA CIV |
| 43547-406 | Clonazepam .5 mg/1 Tablet | Solco Healthcare LLC | ANDA · DEA CIV |
| 43547-407 | Clonazepam 1 mg/1 Tablet | Solco Healthcare LLC | ANDA · DEA CIV |
| 43547-408 | Clonazepam 2 mg/1 Tablet | Solco Healthcare LLC | ANDA · DEA CIV |
| 60760-300 | Clonazepam 1 mg/1 Tablet | St Marys Medical Park Pharmacy | ANDA · DEA CIV |
| 0093-3212 | Clonazepam 1 mg/1 Tablet | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-9294 | Clonazepam 2 mg/1 Tablet, Orally Disintegrating | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-9293 | Clonazepam 1 mg/1 Tablet, Orally Disintegrating | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-9292 | Clonazepam .5 mg/1 Tablet, Orally Disintegrating | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-9291 | Clonazepam .25 mg/1 Tablet, Orally Disintegrating | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-9290 | Clonazepam .125 mg/1 Tablet, Orally Disintegrating | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-3213 | Clonazepam 2 mg/1 Tablet | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 0093-0832 | Clonazepam .5 mg/1 Tablet | Teva Pharmaceuticals USA, Inc. | ANDA · DEA CIV |
| 52817-305 | Clonazepam .25 mg/1 Tablet | TruPharma LLC | ANDA · DEA CIV |
| 87441-021 | Clonazepam .5 mg/1 Tablet | Unit Dose Solutions, Inc. | ANDA · DEA CIV |
| 87441-022 | Clonazepam 1 mg/1 Tablet | Unit Dose Solutions, Inc. | ANDA · DEA CIV |
Clonazepam recalls
- D-0178-2025 Jan 15, 2025 · Class I · Ongoing
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. - D-0179-2025 Jan 15, 2025 · Class I · Ongoing
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. - D-0180-2025 Jan 15, 2025 · Class I · Ongoing
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. - D-0181-2025 Jan 15, 2025 · Class I · Ongoing
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength. - D-0622-2024 Aug 7, 2024 · Class I · Terminated
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.
Frequently asked questions
What is Clonazepam used for?
Seizure Disorders: Clonazepam tablets are useful alone or as an adjunct in the treatment of the Lennox- Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of…
What are the side effects of Clonazepam?
The adverse experiences for clonazepam tablets are provided separately for patients with seizure disorders and with panic disorder. Seizure Disorders: The most frequently occurring side effects of clonazepam tablets are referable to CNS depression. Experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. In some… See the full label for the complete list.
Who makes Clonazepam?
Clonazepam is listed by 31 labelers in the FDA NDC directory, including A-S Medication Solutions, Accord Healthcare Inc., Advagen Pharma Ltd, Advanced Rx of Tennessee, LLC.
Has Clonazepam been recalled?
The FDA enforcement database lists 5 recalls for Clonazepam, most recently D-0178-2025 (class i): Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.